Top

Published in:

01-07-2019 | Glioblastoma | Clinical Study

Effect of patient age on glioblastoma perioperative treatment costs: a value driven outcome database analysis

Authors: Brandon A. Sherrod, Nicholas T. Gamboa, Christopher Wilkerson, Herschel Wilde, Mohammed A. Azab, Michael Karsy, Randy L. Jensen, Sarah T. Menacho

Published in: Journal of Neuro-Oncology | Issue 3/2019

Abstract

Introduction

Identification of groups of patients or interventions with higher associated treatment costs may be beneficial in efforts to decrease the overall financial burden of glioblastoma (GBM) treatment. The authors’ objective was to evaluate perioperative surgical treatment cost differences between elderly and nonelderly patients with GBM using the Value Driven Outcome (VDO) database.

Methods

The authors obtained data from a retrospective cohort of GBM patients treated surgically (resection or biopsy) at their institution from August 2011 to February 2018. Data were compiled using medical records and the VDO database.

Results

A total of 181 patients with GBM were included. Patients were grouped into age < 70 years at time of surgery (nonelderly; n = 121) and ≥ 70 years (elderly; n = 60). Costs were approximately 38% higher in the elderly group on average (each patient was mean 0.68% of total cohort cost vs. 0.49%, p = 0.044). Higher age significantly, but weakly, correlated with higher treatment cost on linear regression analysis (p = 0.007; R² = 0.04). Length of stay was significantly associated with increased cost on linear regression (p < 0.001, R² = 0.84) and was significantly longer in the elderly group (8.7 ± 11.3 vs. 5.2 ± 4.3 days, p = 0.025). The cost breakdown by facility, pharmacy, supply/implants, imaging, and laboratory costs was not significantly different between age groups. Elderly patients with any postoperative complication had 2.1 times greater total costs than those without complication (p = 0.094), 2.9 times greater total costs than nonelderly patients with complication (p = 0.013), and 2.3 times greater total costs than nonelderly patients without complication (p = 0.022).

Conclusions

GBM surgical treatment costs are higher in older patients, particularly those who experience postoperative complications.

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158 CrossRefPubMedPubMedCentral

Ghosh S, Baker S, de Castro DG, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, Dyttus-Cebulok K, Rosenblatt E, Fidarova E, Roa W (2018) Improved cost-effectiveness of short-course radiotherapy in elderly and/or frail patients with glioblastoma. Radiother Oncol 127:114–120. https://doi.org/10.1016/j.radonc.2018.01.017 CrossRefPubMed

Jiang S, Hill K, Patel D, Waldeck AR, Botteman M, Aly A, Norden AD (2017) Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients. J Med Econ 20:1237–1243. https://doi.org/10.1080/13696998.2017.1364258 CrossRefPubMed

Latif AZ, Signorini D, Gregor A, Whittle IR (1998) The costs of managing patients with malignant glioma at a neuro-oncology clinic. Br J Neurosurg 12:118–122CrossRefPubMed

Messali A, Villacorta R, Hay JW (2014) A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics 32:1201–1212. https://doi.org/10.1007/s40273-014-0198-y CrossRefPubMed

Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, Trifilio SM, Grimm SA, Fisher MJ, Haleem MS, Ray PS, McKoy JM, DeBoer R, Tulas KM, Deeb M, McKoy JM (2015) Economics of malignant gliomas: a critical review. J Oncol Pract 11:e59–65. https://doi.org/10.1200/JOP.2012.000560 CrossRefPubMed

Undabeitia J, Torres-Bayona S, Sampron N, Arrazola M, Bollar A, Armendariz M, Torres P, Ruiz I, Caballero MC, Egana L, Querejeta A, Villanua J, Pardo E, Etxegoien I, Liceaga G, Urtasun M, Michan M, Emparanza JI, Aldaz P, Matheu A, Urculo E (2018) Indirect costs associated with glioblastoma: experience at one hospital. Neurologia 33:85–91. https://doi.org/10.1016/j.nrl.2016.05.003 CrossRefPubMed

Mendez I, Jacobs P, MacDougall A, Schultz M (2001) Treatment costs for glioblastoma multiforme in Nova Scotia. Can J Neurol Sci 28:61–65CrossRefPubMed

Ray S, Bonafede MM, Mohile NA (2014) Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am Health Drug Benefits 7:140–149PubMedPubMedCentral

10.

Rong X, Yang W, Garzon-Muvdi T, Caplan JM, Hui X, Lim M, Huang J (2016) Influence of insurance status on survival of adults with glioblastoma multiforme: a population-based study. Cancer 122:3157–3165. https://doi.org/10.1002/cncr.30160 CrossRefPubMed

11.

Pollom EL, Fujimoto DK, Han SS, Harris JP, Tharin SA, Soltys SG (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11–i18. https://doi.org/10.1093/jrr/rrx103 CrossRefPubMedPubMedCentral

12.

Sahebjam S, McNamara M, Mason WP (2012) Management of glioblastoma in the elderly. Clin Adv Hematol Oncol 10:379–386PubMed

13.

Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF (2013) Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg 118:786–798. https://doi.org/10.3171/2012.10.JNS112268 CrossRefPubMed

14.

Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV (2017) Management of glioblastoma in elderly patients. J Neurol Sci 380:250–255. https://doi.org/10.1016/j.jns.2017.07.048 CrossRefPubMed

15.

Halani SH, Babu R, Adamson DC (2017) Management of glioblastoma multiforme in elderly patients: a review of the literature. World Neurosurg 105:53–62. https://doi.org/10.1016/j.wneu.2017.04.153 CrossRefPubMed

16.

Karsy M, Yoon N, Boettcher L, Jensen R, Shah L, MacDonald J, Menacho ST (2018) Surgical treatment of glioblastoma in the elderly: the impact of complications. J Neurooncol 138:123–132. https://doi.org/10.1007/s11060-018-2777-9 CrossRefPubMed

17.

Karsy M, Brock AA, Guan J, Bisson EF, Couldwell WT (2017) Assessment of cost drivers in transsphenoidal approaches for resection of pituitary tumors using the value-driven outcome database. World Neurosurg 105:818–823. https://doi.org/10.1016/j.wneu.2017.05.148 CrossRefPubMed

18.

Karsy M, Guan J, Abou-Al-Shaar H, Eli IM, Kundu B, Bisson EF, Couldwell WT, Dossani RH (2018) Letter to the editor. Effect of facility costs in the treatment of neurosurgical patients using the value driven outcome database. J Neurosurg 129:841–842. https://doi.org/10.3171/2018.3.JNS18725 CrossRefPubMed

19.

Twitchell S, Abou-Al-Shaar H, Reese J, Karsy M, Eli IM, Guan J, Taussky P, Couldwell WT (2018) Analysis of cerebrovascular aneurysm treatment cost: retrospective cohort comparison of clipping, coiling, and flow diversion. Neurosurg Focus 44(5):E3. https://doi.org/10.3171/2018.1.FOCUS17775 CrossRefPubMed

20.

Twitchell S, Karsy M, Reese J, Guan J, Couldwell WT, Dailey A, Bisson EF (2018) Assessment of cost drivers and cost variation for lumbar interbody fusion procedures using the value driven outcomes database. Neurosurg Focus 44(5):E10. https://doi.org/10.3171/2018.1.FOCUS17724 CrossRefPubMed

21.

Lee VS, Kawamoto K, Hess R, Park C, Young J, Hunter C, Johnson S, Gulbransen S, Pelt CE, Horton DJ, Graves KK, Greene TH, Anzai Y, Pendleton RC (2016) Implementation of a value-driven outcomes program to identify high variability in clinical costs and outcomes and association with reduced cost and improved quality. JAMA 316:1061–1072. https://doi.org/10.1001/jama.2016.12226 CrossRefPubMed

22.

Chernew ME, Baicker K, Hsu J (2010) The specter of financial armageddon–health care and federal debt in the United States. N Engl J Med 362:1166–1168. https://doi.org/10.1056/NEJMp1002873 CrossRefPubMed

23.

Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62: 753–764; discussion 764–756. 10.1227/01.neu.0000318159.21731.cf

24.

Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O (2018) One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neurooncol 140:385–391. https://doi.org/10.1007/s11060-018-2964-8 CrossRefPubMed

25.

Chibbaro S, Di Rocco F, Makiese O, Mirone G, Marsella M, Lukaszewicz AC, Vicaut E, Turner B, Hamdi S, Spiriev T, Di Emidio P, Pirracchio R, Payen D, George B, Bresson D (2010) Neurosurgery and elderly: analysis through the years. Neurosurg Rev 34:229–234. https://doi.org/10.1007/s10143-010-0301-6 CrossRefPubMed

26.

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP, Trial I (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977 CrossRefPubMed

27.

Park M, Lee SK, Chang JH, Kang SG, Kim EH, Kim SH, Song MK, Ma BG, Ahn SS (2017) Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model? J Neurooncol 134:423–431. https://doi.org/10.1007/s11060-017-2544-3 CrossRefPubMed

28.

Moroney C, Perry JR, Tsang DS, Bilodeau D, Mueller C, Soliman H, Myrehaug S, Sahgal A, Tseng CL, Tsao MN (2017) Hospitalizations in elderly glioblastoma patients. Ann Palliat Med 6:S161–S169. https://doi.org/10.21037/apm.2017.06.02 CrossRefPubMed

29.

Guedes de Castro D, Matiello J, Roa W, Ghosh S, Kepka L, Kumar N, Sinaika V, Lomidze D, Hentati D, Rosenblatt E, Fidarova E (2017) Survival outcomes with short-course radiation therapy in elderly patients with glioblastoma: data from a randomized phase 3 trial. Int J Radiat Oncol Biol Phys 98:931–938. https://doi.org/10.1016/j.ijrobp.2017.03.037 CrossRefPubMed

30.

Furlan JC, Fehlings MG, Craven BC (2018) Economic impact of aging on the initial spine care of patients with acute spine trauma: from bedside to teller. Neurosurgery. https://doi.org/10.1093/neuros/nyy180

31.

Bekelis K, Gottlieb DJ, Su Y, Lanzino G, Lawton MT, MacKenzie TA (2017) Medicare expenditures for elderly patients undergoing surgical clipping or endovascular intervention for subarachnoid hemorrhage. J Neurosurg 126:805–810. https://doi.org/10.3171/2016.2.JNS152994 CrossRefPubMed

32.

Li A, Azad TD, Veeravagu A, Bhatti I, Long C, Ratliff JK, Li G (2017) Cranioplasty complications and costs: a national population-level analysis using the marketscan longitudinal database. World Neurosurg 102:209–220. https://doi.org/10.1016/j.wneu.2017.03.022 CrossRefPubMed

33.

Himmelstein DU, Thorne D, Warren E, Woolhandler S (2009) Medical bankruptcy in the United States, 2007: results of a national study. Am J Med 122:741–746. https://doi.org/10.1016/j.amjmed.2009.04.012 CrossRefPubMed

34.

Gordon DD, Patel I, Pellegrini AM, Perlis RH (2018) Prevalence and nature of financial considerations documented in narrative clinical records in intensive care units. JAMA Netw Open 1:e184178. https://doi.org/10.1001/jamanetworkopen.2018.4178 CrossRefPubMedPubMedCentral

35.

Zheng Z, Han X, Guy GP Jr, Davidoff AJ, Li C, Banegas MP, Ekwueme DU, Yabroff KR, Jemal A (2017) Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer 123:1453–1463. https://doi.org/10.1002/cncr.30560 CrossRefPubMedPubMedCentral

36.

Benedetto N, Gambacciani C, Montemurro N, Morganti R, Perrini P (2017) Surgical management of acute subdural haematomas in elderly: report of a single center experience. Br J Neurosurg 31:244–248. https://doi.org/10.1080/02688697.2016.1244249 CrossRefPubMed

37.

Park J, Woo H, Kang DH, Kim Y (2014) Critical age affecting 1-year functional outcome in elderly patients aged ≥70 years with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien) 156:1655–1661. https://doi.org/10.1007/s00701-014-2133-6 CrossRef

Title: Effect of patient age on glioblastoma perioperative treatment costs: a value driven outcome database analysis
Authors: Brandon A. Sherrod
Nicholas T. Gamboa
Christopher Wilkerson
Herschel Wilde
Mohammed A. Azab
Michael Karsy
Randy L. Jensen
Sarah T. Menacho
Publication date: 01-07-2019
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Published in: Journal of Neuro-Oncology / Issue 3/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03178-z

At a glance: The STEP trials

Springer Medicine

Effect of patient age on glioblastoma perioperative treatment costs: a value driven outcome database analysis

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system

Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial

Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

Nomograms for predicting the overall and cause-specific survival in patients with malignant peripheral nerve sheath tumor: a population-based study

Satellite lesions of DNET: implications for seizure and tumor control after resection